Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithiumPsychiatry Publications and Presentations
UMMS AffiliationDepartment of Psychiatry
SubjectsAnticonvulsants; Antimanic Agents; Depressive Disorder; Drug Monitoring; Epilepsy; Female; Humans; Lithium Compounds; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Serotonin Uptake Inhibitors; Triazines
AbstractRecently, guidelines for antenatal management of depression were published.1 Psychotherapy alone may be an appropriate treatment for some women, while psychopharmacotherapy may be indicated in others. Use of psychopharmacotherapy during pregnancy and the postpartum involves complex clinical decisions based on the risks and benefits and alternatives to medications. The aim of effective treatment is to minimize maternal and fetal exposure to psychiatric illness by optimally treating it with the minimum effective dose regimen. One variable that complicates psychopharmacotherapy is that dosing often requires adjustment to maintain therapeutic effects, particularly in late pregnancy. The current article focuses on those factors that affect dosing in pregnancy.
SourceDeligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: Recommendations for SSRIs, lamotrigine and lithium. Journal of Clinical Psychiatry 71(5):649-650, 2010.
Related ResourcesLink to article in PubMed
Citation InformationKristina M. Deligiannidis. "Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium" Vol. 71 Iss. 5 (2010) ISSN: 1555-2101
Available at: http://works.bepress.com/kristina_deligiannidis/2/